Together, our studies pointed to betacellulin (BTC), one of several epidermal growth factor receptor (EGFR) agonists, as a master regulatory molecule that was downregulated by ω3 PUFA in the NASH liver. The gene discussed is BTC; the disease is metabolic dysfunction-associated steatohepatitis.